These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 4056079)

  • 21. The rise and fall of serum theophylline concentration: a comparison of sustained-release formulations in volunteers with rapid theophylline clearance.
    Mucklow JC; Kuhn S
    Br J Clin Pharmacol; 1985 Dec; 20(6):589-96. PubMed ID: 4091990
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium.
    Rojanasthien N; Kovjiriyapan K; Manorot M; Pothirat C
    Asian Pac J Allergy Immunol; 2001 Jun; 19(2):69-78. PubMed ID: 11699723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Theo-Dur: no loss of sustained-release effect with chewing or crushing.
    MacKintosh DA; Baird-Lambert J; Buchanan N
    Aust N Z J Med; 1985 Jun; 15(3):351-2. PubMed ID: 3864429
    [No Abstract]   [Full Text] [Related]  

  • 24. Conversion from intravenous to sustained-release oral theophylline in pediatric patients with asthma.
    Clarke DF; Werbowsky OL; Grodin MA; Shargel L
    Drug Intell Clin Pharm; 1986 Sep; 20(9):700-3. PubMed ID: 3757784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of whole and half Theo-Dur tablets.
    Fagerström PO
    Eur J Respir Dis Suppl; 1980; 109():62-6. PubMed ID: 6934089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Absorption of sustained-release theophylline tablets.
    Fagerström PO; Heintz L
    Int J Clin Pharmacol Ther Toxicol; 1983 Jul; 21(7):359-62. PubMed ID: 6885207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sustained-release theophylline. Pharmacokinetic and therapeutic comparison of two preparations.
    Menendez R; Kelly HW; Howick J; McWilliams BC
    Am J Dis Child; 1983 May; 137(5):469-73. PubMed ID: 6846276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bioavailability and pharmacokinetics of theophylline in plain uncoated and sustained-release dosage forms in relation to smoking habit. I. Single dose study.
    Horai Y; Ishizaki T; Sasaki T; Chiba K; Suganuma T; Echizen H; Ohnishi A
    Eur J Clin Pharmacol; 1983; 24(1):79-87. PubMed ID: 6832206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Application of stable isotope methodology in the evaluation of sustained-release theophylline dosage forms.
    Koup JR; Walker SB; Shapiro GG; Howald WN; Pierson WE; Bierman CW; Furukawa CT
    J Allergy Clin Immunol; 1986 Oct; 78(4 Pt 2):752-4. PubMed ID: 3771962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioavailability of four slow-release theophylline formulations in the beagle dog.
    Koritz GD; McKiernan BC; Neff-Davis CA; Munsiff IJ
    J Vet Pharmacol Ther; 1986 Sep; 9(3):293-302. PubMed ID: 3761420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical use of controlled-release theophylline in chronic airways obstruction.
    Dal Negro R; Turco P; Pomari C; Cordaro CI
    J Int Med Res; 1987; 15(6):391-6. PubMed ID: 3436486
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conversion from intravenous to oral dosing using sustained-release theophylline tablets.
    Stein GE; Haughey DB; Ross RJ; Vakoutis J
    Drug Intell Clin Pharm; 1982 Oct; 16(10):772-4. PubMed ID: 7140514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conversion of COPD patients from multiple to single dose theophylline. Serum levels and symptom comparison.
    Chetty KG; Despars JA; Giron A; Light RW
    Chest; 1991 Oct; 100(4):1064-7. PubMed ID: 1914559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Theophylline absorption from sustained-release products: comparative steady-state bioavailability of once-daily Theo-Dur, Theo-24, and Uniphyl.
    Hurwitz A; Karim A; Burns TS
    J Clin Pharmacol; 1987 Nov; 27(11):855-61. PubMed ID: 3429692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum theophylline concentrations and pulmonary function tests after administration of two sustained-release formulations containing theophylline in patients affected by chronic obstructive lung disease.
    Fontana G; Cresci F; Lo Sapio P; Panuccio P
    Int J Clin Pharmacol Res; 1987; 7(5):351-6. PubMed ID: 3667008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses.
    Schuppan D; Molz KH; Staib AH; Rietbrock N
    Int J Clin Pharmacol Ther Toxicol; 1981 May; 19(5):223-7. PubMed ID: 7251238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of parenteral aminophylline in patients taking slow release theophylline preparations: an observation of clinical practice.
    Arbab OA; Wiggins J; Ayres JG; Stableforth DE
    Br J Dis Chest; 1985 Apr; 79(2):161-71. PubMed ID: 3986120
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of dosing time on the pharmacokinetics and pharmacodynamics of a 'once-a-day' sustained release theophylline preparation.
    Lamont H; Pauwels R; Van der Straeten M
    Br J Clin Pharmacol; 1987 Dec; 24(6):735-42. PubMed ID: 3440095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical trial of a sustained release theophylline tablet in adult asthmatics.
    Dhand R; Malik SK; Garg SK; Bhutani JK; Swaminathan S
    Indian J Chest Dis Allied Sci; 1986; 28(4):212-21. PubMed ID: 3301644
    [No Abstract]   [Full Text] [Related]  

  • 40. Food-induced changes in theophylline absorption from controlled-release formulations. Part I. Substantial increased and decreased absorption with Uniphyl tablets and Theo-Dur Sprinkle.
    Karim A; Burns T; Wearley L; Streicher J; Palmer M
    Clin Pharmacol Ther; 1985 Jul; 38(1):77-83. PubMed ID: 4006379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.